{"altmetric_id": 85019710, "counts": {"readers": {"citeulike": "0", "mendeley": "28", "connotea": "0"}, "total": {"posts_count": 105}, "twitter": {"unique_users_count": 48, "posts_count": 66}, "news": {"unique_users_count": 20, "unique_users": ["the_medical_news", "ticker_tech", "stockwatch", "pr_newswire", "morning_star", "finanzen", "ariva", "finanzen_ch", "wfmz_tv_69", "kpvi", "biospace", "marketscreener", "crwe_world", "spoke", "jotup", "nasdaq", "the_street", "benzinga", "gurufocus", "pressreleasepoint"], "posts_count": 39}}, "citation": {"altmetric_jid": "532721422a83ee84788b4567", "authors": ["Alimova, Maria", "Sidhom, Eriene-Heidi", "Satyam, Abhigyan", "Dvela-Levitt, Moran", "Melanson, Michelle", "Chamberlain, Brian T.", "Alper, Seth L.", "Santos, Jean", "Gutierrez, Juan", "Subramanian, Ayshwarya", "Grinkevich, Elizabeth", "Bricio, Estefania Reyes", "Kim, Choah", "Clark, Abbe", "Watts, Andrew", "Thompson, Rebecca", "Marshall, Jamie", "Pablo, Juan Lorenzo", "Coraor, Juliana", "Roignot, Julie", "Vernon, Katherine A.", "Keller, Keith", "Campbell, Alissa", "Emani, Maheswarareddy", "Racette, Matthew", "Bazua-Valenti, Silvana", "Padovano, Valeria", "Weins, Astrid", "McAdoo, Stephen P.", "Tam, Frederick W.K.", "Ronco, Lucienne", "Wagner, Florence", "Tsokos, George C.", "Shaw, Jillian L.", "Greka, Anna"], "doi": "10.1101/2020.06.30.180380", "first_seen_on": "2020-07-01T04:17:57+00:00", "funders": ["niaid"], "issns": [], "journal": "bioRxiv", "last_mentioned_on": 1621017020, "links": ["https://www.biorxiv.org/content/10.1101/2020.06.30.180380v1", "https://www.biorxiv.org/content/10.1101/2020.06.30.180380v1?rss=1%22", "https://www.biorxiv.org/content/10.1101/2020.06.30.180380v1.full", "http://biorxiv.org/cgi/content/short/2020.06.30.180380v1", "https://pubmed.ncbi.nlm.nih.gov/32637960/?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter", "http://dx.doi.org/10.1101/2020.06.30.180380", "https://doi.org/10.1101/2020.06.30.180380", "https://doi.org/10.1101/2020.06.30.180380%20", "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337390/", "https://c212.net/c/link/?t=0&l=en&o=2920250-1&h=3863790163&u=https://doi.org/10.1101/2020.06.30.180380&a=https://doi.org/10.1101/2020.06.30.180380"], "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/06/30/2020.06.30.180380.full.pdf", "pmid": "32637960", "publisher": "Cold Spring Harbor Laboratory", "title": "A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic", "type": "article", "mendeley_url": "https://www.mendeley.com/catalogue/a85a8de7-8aee-3a09-b734-0f8256901903/"}, "altmetric_score": {"score": 170.05, "score_history": {"1y": 170.05, "6m": 1.1, "3m": 1.1, "1m": 0.25, "1w": 0.25, "6d": 0.25, "5d": 0.25, "4d": 0, "3d": 0, "2d": 0, "1d": 0, "at": 170.05}, "context_for_score": {"all": {"total_number_of_other_articles": 17759439, "mean": 9.45271436671, "rank": 133004, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 17628438, "rank_type": "exact", "sample_size": 17759439, "percentile": 99}, "similar_age_3m": {"total_number_of_other_articles": 294995, "mean": 19.350054719571, "rank": 5287, "this_scored_higher_than_pct": 98, "this_scored_higher_than": 289704, "rank_type": "exact", "sample_size": 294995, "percentile": 98}, "this_journal": {"total_number_of_other_articles": 121674, "mean": 13.893120009205, "rank": 766, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 120911, "rank_type": "exact", "sample_size": 121674, "percentile": 99}, "similar_age_this_journal_3m": {"total_number_of_other_articles": 8401, "mean": 15.290814188787, "rank": 79, "this_scored_higher_than_pct": 99, "this_scored_higher_than": 8322, "rank_type": "exact", "sample_size": 8401, "percentile": 99}}}, "demographics": {"poster_types": {"member_of_the_public": 31, "researcher": 13, "practitioner": 4}, "users": {"twitter": {"cohorts": {"Members of the public": 31, "Scientists": 13, "Practitioners (doctors, other healthcare professionals)": 4}}, "mendeley": {"by_status": {"Student  > Postgraduate": 2, "Professor > Associate Professor": 1, "Researcher": 6, "Student  > Ph. D. Student": 3, "Student  > Bachelor": 3, "Student  > Doctoral Student": 1, "Lecturer": 1, "Other": 5, "Librarian": 4}, "by_discipline": {"Medicine and Dentistry": 11, "Economics, Econometrics and Finance": 1, "Immunology and Microbiology": 1, "Computer Science": 1, "Agricultural and Biological Sciences": 1, "Nursing and Health Professions": 2, "Mathematics": 1, "Biochemistry, Genetics and Molecular Biology": 4, "Pharmacology, Toxicology and Pharmaceutical Science": 1, "Environmental Science": 1, "Unspecified": 1}}}, "geo": {"twitter": {"US": 22, "AT": 1, "MX": 1, "GB": 6, "IN": 1, "DE": 1}}}, "posts": {"twitter": [{"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1949132852"}, "tweet_id": "1278180954302005248"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "748954950894383104"}, "tweet_id": "1278180955191205890"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "57106800"}, "tweet_id": "1278426484416417794"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "248310208"}, "tweet_id": "1278428088167170048"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "3862027438"}, "tweet_id": "1278452118832263169"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1265336030833422337"}, "tweet_id": "1278766899631812609"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "3871255601"}, "tweet_id": "1279120474820284416"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "49691913"}, "tweet_id": "1279122166793920517"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "3404399200"}, "tweet_id": "1279137635731111937"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "228957553"}, "tweet_id": "1279185514973855746"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1852567092"}, "tweet_id": "1279608805991632899"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1279421563813662720"}, "tweet_id": "1280041107217317888"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1135916701759840256"}, "tweet_id": "1280134719292821504"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "19313587"}, "tweet_id": "1280216781613907972"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "3871255601"}, "tweet_id": "1280222455458672640"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "2838295565"}, "tweet_id": "1280258092601692161"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "3871255601"}, "tweet_id": "1280259063058661383"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "759391249099005952"}, "tweet_id": "1280259480341577729"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "759391249099005952"}, "tweet_id": "1280259497571819520"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "114492923"}, "tweet_id": "1280301871899373568"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "3871255601"}, "tweet_id": "1280302919980646400"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "2392141413"}, "tweet_id": "1280305365545074689"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "114492923"}, "tweet_id": "1280305677978660864"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "776636076689596416"}, "tweet_id": "1280309554685886464"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1134960025670230016"}, "tweet_id": "1280321428102004737"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "870565430657785856"}, "tweet_id": "1280357970019139584"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1135916701759840256"}, "tweet_id": "1280430237059362817"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "3224242123"}, "tweet_id": "1280453328913272834"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1280672372618600448"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1280672394357719047"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "967426131371724801"}, "tweet_id": "1280736772717232128"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "947875442"}, "tweet_id": "1280859433384448000"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "114492923"}, "tweet_id": "1280950922265403393"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1173978345601667073"}, "tweet_id": "1280976297011957760"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1173978345601667073"}, "tweet_id": "1280976650788896772"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "116013140"}, "tweet_id": "1281024450805338113"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "2843162441"}, "tweet_id": "1281183870646456320"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "2351689470"}, "tweet_id": "1281208614099640320"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1066362345029545984"}, "tweet_id": "1281409563644682241"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1282133147904348160"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1282133169567825920"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "4739609663"}, "tweet_id": "1282653994855419904"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "2598246906"}, "tweet_id": "1282654258601635845"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "62871181"}, "tweet_id": "1282654335797788675"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "733717446"}, "tweet_id": "1282674688607391744"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "487787278"}, "tweet_id": "1282748497385721856"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1070673693624451073"}, "tweet_id": "1282890235962064897"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "510816105"}, "tweet_id": "1283018918857252864"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1283534096933806080"}, "tweet_id": "1283855123471630337"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "2598246906"}, "tweet_id": "1287539683904368640"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1240836313236017154"}, "tweet_id": "1287590638020710401"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "72676037"}, "tweet_id": "1288082286857146370"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1283534096933806080"}, "tweet_id": "1288652240232878080"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "32282868"}, "tweet_id": "1289023627203981312"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "32282868"}, "tweet_id": "1289970276671733760"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1248991075685072897"}, "tweet_id": "1292015909075390465"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1281540117518311424"}, "tweet_id": "1293845550350110720"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "925137614205784065"}, "tweet_id": "1298642954081325063"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "1135916701759840256"}, "tweet_id": "1298915791807619073"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "21392458"}, "tweet_id": "1299238165102854144"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "3198034077"}, "tweet_id": "1299238866189266946"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "2598246906"}, "tweet_id": "1300181595073241089"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "3688469536"}, "tweet_id": "1364957900297424910"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "990791084"}, "tweet_id": "1392569090225623042"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "990791084"}, "tweet_id": "1393259102592196609"}, {"license": "gnip", "citation_ids": [85019710], "author": {"tweeter_id": "990791084"}, "tweet_id": "1393272485290852355"}], "news": [{"title": "Repurposed drug for acute lung injury in COVID-19", "url": "http://ct.moreover.com/?a=42499209165&p=1pl&v=1&x=9x2FOhGXAOh_GlU6ZwedFA", "license": "public", "citation_ids": [85019710], "posted_on": "2020-07-02T04:01:13+00:00", "summary": "In the current COVID-19 pandemic, drug repurposing is being widely investigated as a way to find treatments rapidly.", "author": {"name": "The Medical News", "url": "http://www.news-medical.net/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/000/146/normal/image.png?1369927508"}}, {"title": "Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia", "url": "http://ct.moreover.com/?a=42594425633&p=1pl&v=1&x=5B4k6znMi-eCA6HKgAjBtA", "license": "public", "citation_ids": [85019710, 85019710], "posted_on": "2020-07-14T11:34:18+00:00", "summary": "High content screen identifies fostamatinib as a candidate for repurposing for Acute Lung Injury SOUTH SAN FRANCISCO, Calif.", "author": {"name": "Ticker Tech", "url": "http://www.tickertech.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/724/normal/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}}, {"title": "Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia", "url": "http://ct.moreover.com/?a=42594442648&p=1pl&v=1&x=4HM3scCK6b2wpiHnS3ab3Q", "license": "public", "citation_ids": [85019710, 85019710], "posted_on": "2020-07-14T11:36:32+00:00", "summary": "High content screen identifies fostamatinib as a candidate for repurposing for Acute Lung Injury SOUTH SAN FRANCISCO, Calif.", "author": {"name": "Stockwatch", "url": "https://www.stockwatch.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/797/normal/Capture19.PNG?1576480973"}}, {"title": "Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia", "url": "http://ct.moreover.com/?a=42594448024&p=1pl&v=1&x=5Dk4X5RrEKt2YxRlrLf6JA", "license": "public", "citation_ids": [85019710, 85019710], "posted_on": "2020-07-14T11:30:00+00:00", "summary": "High content screen identifies fostamatinib as a candidate for repurposing for Acute Lung Injury SOUTH SAN FRANCISCO, Calif.", "author": {"name": "PR Newswire", "url": "http://www.prnewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/545/normal/Screen_Shot_2016-01-06_at_16.29.18.png?1452097789"}}, {"title": "Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia", "url": "http://ct.moreover.com/?a=42594447797&p=1pl&v=1&x=XCU6Dzmbp8LkUmjFDGLu7g", "license": "public", "citation_ids": [85019710, 85019710], "posted_on": "2020-07-14T11:30:00+00:00", "summary": "Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia High content screen identifies fostamatinib as a candidate for repurposing for Acute Lung Injury PR Newswire SOUTH SAN FRANCISCO, Calif., July 14, 2020\u2026", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia", "url": "http://ct.moreover.com/?a=42594448754&p=1pl&v=1&x=EXXk-YUnhXw55mfAVEHHJg", "license": "public", "citation_ids": [85019710, 85019710], "posted_on": "2020-07-14T11:37:04+00:00", "summary": ", /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase \u2026", "author": {"name": "Finanzen", "url": "https://www.finanzen.at/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/571/normal/Capture25.PNG?1575885785"}}, {"title": "Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia", "url": "http://ct.moreover.com/?a=42594490661&p=1pl&v=1&x=FMGqcbuInNVaAQmnmBGFvw", "license": "public", "citation_ids": [85019710, 85019710], "posted_on": "2020-07-14T11:35:29+00:00", "summary": "Rigel Pharmaceuticals-Aktie dauerhaft f\u00fcr 0 Euro handeln! Jetzt auf Smartbroker.de PR Newswire SOUTH SAN FRANCISCO, Calif., July 14, 2020 SOUTH SAN FRANCISCO, Calif.", "author": {"name": "Ariva", "url": "http://www.ariva.de", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/907/normal/Screen_Shot_2016-01-27_at_14.41.07.png?1453905685"}}, {"title": "Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia", "url": "http://ct.moreover.com/?a=42594500331&p=1pl&v=1&x=U-xw5hqIv0Jy6Bu0FANGEA", "license": "public", "citation_ids": [85019710, 85019710], "posted_on": "2020-07-14T11:43:58+00:00", "summary": "/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase (SY\u2026", "author": {"name": "Finanzen.ch", "url": "https://www.finanzen.ch/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/573/normal/Capture26.PNG?1575886265"}}, {"title": "Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia", "url": "http://ct.moreover.com/?a=42594572672&p=1pl&v=1&x=T8QxgNAaR5Gk_yMwL6WLzQ", "license": "public", "citation_ids": [85019710, 85019710], "posted_on": "2020-07-14T11:30:00+00:00", "summary": "/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase (SY\u2026", "author": {"name": "WFMZ-TV 69", "url": "https://www.wfmz.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/256/normal/Capture_62.PNG?1567141986"}}, {"title": "Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia", "url": "http://ct.moreover.com/?a=42594696138&p=1pl&v=1&x=DaLo17dzlHZgC7t9KtLcfA", "license": "public", "citation_ids": [85019710, 85019710], "posted_on": "2020-07-14T11:30:00+00:00", "summary": "/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase (SY\u2026", "author": {"name": "KPVI", "url": "https://www.kpvi.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/663/normal/Capture_kvpi.PNG?1576132656"}}, {"title": "Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia", "url": "http://ct.moreover.com/?a=42598913339&p=1pl&v=1&x=uZgPSLLTjwn2RrZuJEFsxg", "license": "public", "citation_ids": [85019710, 85019710], "posted_on": "2020-07-14T00:00:00+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., July 14, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "Biospace", "url": "http://www.biospace.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/375/normal/biospace.png?1437140433"}}, {"title": "RIGEL PHARMACEUTICALS : Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia", "url": "http://ct.moreover.com/?a=42594417921&p=1pl&v=1&x=4YEP9qFTcIxlDXJO9OwwzA", "license": "public", "citation_ids": [85019710, 85019710], "posted_on": "2020-07-14T11:31:05+00:00", "summary": "/PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase (SY\u2026", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program", "url": "http://ct.moreover.com/?a=42761865426&p=1pl&v=1&x=lbRj5sp4h3oHGRzBLl0TWg", "license": "public", "citation_ids": [85730808, 85019710, 84692664, 84692664, 85019710, 85730808, 85730808, 85019710, 84692664], "posted_on": "2020-08-04T20:01:00+00:00", "summary": "Second quarter net product sales of $15.0 million, a year-over-year increase of 47% University of Amsterdam in vitro studies showed fostamatinib blocked macrophage hyper-inflammatory response to serum from severe COVID-19 patients Appointed 30-year\u2026", "author": {"name": "PR Newswire", "url": "http://www.prnewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/545/normal/Screen_Shot_2016-01-06_at_16.29.18.png?1452097789"}}, {"title": "RIGEL PHARMACEUTICALS : Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program", "url": "http://ct.moreover.com/?a=42761877152&p=1pl&v=1&x=3tlghGR1TXfuE-U57-VvMw", "license": "public", "citation_ids": [85730808, 85019710, 84692664, 84692664, 85019710, 85730808, 85730808, 85019710, 84692664], "posted_on": "2020-08-04T20:02:13+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Aug. 4, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program", "url": "http://ct.moreover.com/?a=42761881479&p=1pl&v=1&x=B_CD5HqwJ__iGDWN3QRmsw", "license": "public", "citation_ids": [85730808, 85019710, 84692664, 84692664, 85019710, 85730808], "posted_on": "2020-08-04T20:05:42+00:00", "summary": "Rigel Pharmaceuticals-Aktie dauerhaft f\u00fcr 0 Euro handeln! Jetzt auf Smartbroker.de PR Newswire SOUTH SAN FRANCISCO, Calif., Aug.", "author": {"name": "Ariva", "url": "http://www.ariva.de", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/907/normal/Screen_Shot_2016-01-27_at_14.41.07.png?1453905685"}}, {"title": "Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program", "url": "http://ct.moreover.com/?a=42761882439&p=1pl&v=1&x=GPt-qchG4jaP-APAWjN2mQ", "license": "public", "citation_ids": [85730808, 85019710, 84692664, 84692664, 85019710, 85730808, 85730808, 85019710, 84692664], "posted_on": "2020-08-04T20:08:01+00:00", "summary": "Second quarter net product sales of $15.0 million, a year-over-year increase of 47% University of Amsterdam in vitro studies showed fostamatinib blocked macrophage hyper-inflammatory response to serum from severe COVID-19 patients Appointed 30-year\u2026", "author": {"name": "Crwe World", "url": "http://crweworld.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/344/normal/Capture_crwe.PNG?1574923200"}}, {"title": "Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program", "url": "http://ct.moreover.com/?a=42761892930&p=1pl&v=1&x=YLravIM8FbKeHP2f9FTJMA", "license": "public", "citation_ids": [85730808, 85019710, 84692664, 84692664, 85019710, 85730808, 85730808, 85019710, 84692664], "posted_on": "2020-08-04T20:01:00+00:00", "summary": "Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program Second quarter net product sales of $15.0 million, a year-over-year increase of 47% University of Amsterdam in vitro studies showed\u2026", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program", "url": "http://ct.moreover.com/?a=42761897545&p=1pl&v=1&x=08tFqqt4J2ooAI0SDLA4Og", "license": "public", "citation_ids": [85730808, 85019710, 84692664, 84692664, 85019710, 85730808], "posted_on": "2020-08-04T20:01:00+00:00", "summary": ", /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended, including sales of TAVALISSE \u00ae (fostamatinib disodium hexahydrate) tablets, for the treatment of adults with chronic immune\u2026", "author": {"name": "Finanzen", "url": "https://www.finanzen.at/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/571/normal/Capture25.PNG?1575885785"}}, {"title": "Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program", "url": "http://ct.moreover.com/?a=42761898177&p=1pl&v=1&x=7Iw63-jcmd9JJP-XxdOnHA", "license": "public", "citation_ids": [85730808, 85019710, 84692664, 84692664, 85019710, 85730808, 85730808, 85019710, 84692664], "posted_on": "2020-08-04T20:01:00+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Aug. 4, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "Finanzen.ch", "url": "https://www.finanzen.ch/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/573/normal/Capture26.PNG?1575886265"}}, {"title": "Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program", "url": "http://ct.moreover.com/?a=42761920328&p=1pl&v=1&x=Sha0IQhqiVzp58YpJrbOOQ", "license": "public", "citation_ids": [85730808, 85019710, 84692664, 84692664, 85019710, 85730808, 85730808, 85019710, 84692664], "posted_on": "2020-08-04T20:16:06+00:00", "summary": "Second quarter net product sales of $15.0 million, a year-over-year increase of 47% University of Amsterdam in vitro studies showed fostamatinib blocked macrophage hyper-inflammatory response to serum from severe COVID-19 patients Appointed 30-year\u2026", "author": {"name": "Spoke", "url": "http://www.spoke.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/787/normal/Capture14.PNG?1576476237"}}, {"title": "Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program", "url": "http://ct.moreover.com/?a=42762053381&p=1pl&v=1&x=vMN3ygFwb8pDvjzbDCF29Q", "license": "public", "citation_ids": [85730808, 85019710, 84692664, 84692664, 85019710, 85730808, 85730808, 85019710, 84692664], "posted_on": "2020-08-04T20:01:00+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Aug. 4, 2020 /PRNewswire/ --. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2020, including sales of TAVALISSE \u00ae (fostamatinib disodium hexahydrate) tablets, for the treatment\u2026", "author": {"name": "KPVI", "url": "https://www.kpvi.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/663/normal/Capture_kvpi.PNG?1576132656"}}, {"title": "Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program", "url": "http://ct.moreover.com/?a=42762062907&p=1pl&v=1&x=zi70Flzrycf0tByChtHCjg", "license": "public", "citation_ids": [85730808, 85019710, 84692664], "posted_on": "2020-08-04T20:38:13+00:00", "summary": "\"During the second quarter we achieved significant progress across all aspects of our business, despite the challenges resulting from the COVID-19 pandemic,\" said Raul Rodriguez, Rigel's president and CEO.", "author": {"name": "Jotup", "url": "https://jotup.co/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/231/normal/jotup-logo.png?1567071493"}}, {"title": "Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program", "url": "http://ct.moreover.com/?a=42763405684&p=1pl&v=1&x=rYHY1GfUqyK2YyaS08l1cQ", "license": "public", "citation_ids": [85730808, 85019710, 84692664, 84692664, 85019710, 85730808, 85730808, 85019710, 84692664], "posted_on": "2020-08-05T01:02:38+00:00", "summary": "Second quarter net product sales of $15.0 million, a year-over-year increase of 47% University of Amsterdam in vitro studies showed fostamatinib blocked macrophage hyper-inflammatory response to serum from severe COVID-19 patients Appointed 30-year\u2026", "author": {"name": "NASDAQ", "url": "http://www.nasdaq.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/839/normal/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097175499&p=1pl&v=1&x=TuliH3QGQmQ8ALx-ILJccA", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T11:30:00+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ --. (Nasdaq: RIGL ) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of\u2026", "author": {"name": "PR Newswire", "url": "http://www.prnewswire.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/545/normal/Screen_Shot_2016-01-06_at_16.29.18.png?1452097789"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097190335&p=1pl&v=1&x=zFXoeld9jedS0OicNikvEQ", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T11:36:01+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "Stockwatch", "url": "https://www.stockwatch.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/797/normal/Capture19.PNG?1576480973"}}, {"title": "RIGEL PHARMACEUTICALS : Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097191460&p=1pl&v=1&x=1viwVZVFj3wEXZJVALdIog", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T11:31:07+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "MarketScreener", "url": "https://www.marketscreener.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/689/normal/screen.PNG?1576146564"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097211649&p=1pl&v=1&x=cqDp7YroLq-MySz5cnmwbA", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T11:30:00+00:00", "summary": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova PR Newswire SOUTH SAN FRANCISCO, Calif., Sept.", "author": {"name": "Morning Star", "url": "https://www.morningstar.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/002/912/normal/Screen_Shot_2018-09-17_at_18.20.59.png?1537204915"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097214019&p=1pl&v=1&x=X2338T3Ff5qwd-pEEB6u5A", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T11:38:12+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "Ticker Tech", "url": "http://www.tickertech.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/724/normal/Screen_Shot_2016-01-26_at_15.37.40.png?1453822700"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097237353&p=1pl&v=1&x=2bBxerAevIihhf4gDbMe8g", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258], "posted_on": "2020-09-17T11:41:14+00:00", "summary": ", /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19\u2026", "author": {"name": "Finanzen", "url": "https://www.finanzen.at/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/571/normal/Capture25.PNG?1575885785"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097244935&p=1pl&v=1&x=J2qFdE6iVsRU_wjTtIyf8A", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258], "posted_on": "2020-09-17T11:35:30+00:00", "summary": "Rigel Pharmaceuticals-Aktie dauerhaft f\u00fcr 0 Euro handeln! Jetzt auf Smartbroker.de PR Newswire SOUTH SAN FRANCISCO, Calif., Sept.", "author": {"name": "Ariva", "url": "http://www.ariva.de", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/907/normal/Screen_Shot_2016-01-27_at_14.41.07.png?1453905685"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097265503&p=1pl&v=1&x=46Oxg1bl3ROb_x2AF6N-0w", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T11:46:38+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "Finanzen.ch", "url": "https://www.finanzen.ch/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/573/normal/Capture26.PNG?1575886265"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial Of Fostamatinib In Hospitalized COVID-19 Patients In Collaboration With Inova", "url": "http://ct.moreover.com/?a=43097267978&p=1pl&v=1&x=K_ri73NqQ4968-crWi4mbg", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T11:30:00+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "The Street", "url": "http://www.thestreet.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/809/normal/Screen_Shot_2016-01-27_at_10.05.56.png?1453889412"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097301082&p=1pl&v=1&x=g55FT6dw-eTWzYgCtC-Rpg", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T11:30:00+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "Benzinga", "url": "http://www.benzinga.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/738/normal/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097302449&p=1pl&v=1&x=--LsDfO5mdVXKUqdZJcdhQ", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T11:52:07+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "Biospace", "url": "http://www.biospace.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/375/normal/biospace.png?1437140433"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097357197&p=1pl&v=1&x=m2YDESY1X8IBPqEnkb9s2A", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T11:30:00+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ --. (Nasdaq: RIGL) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of\u2026", "author": {"name": "WFMZ-TV 69", "url": "https://www.wfmz.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/003/256/normal/Capture_62.PNG?1567141986"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097394081&p=1pl&v=1&x=cQCkjuKZQHYBTzTRL-6IRA", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T11:30:00+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ --. (Nasdaq: RIGL) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of\u2026", "author": {"name": "KPVI", "url": "https://www.kpvi.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/663/normal/Capture_kvpi.PNG?1576132656"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43097844013&p=1pl&v=1&x=T2MOCpnJ834txDrx6_MAkQ", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T13:02:36+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "NASDAQ", "url": "http://www.nasdaq.com", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/001/839/normal/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43098206056&p=1pl&v=1&x=DFAmseYlv10yuVW7qISO8Q", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T13:49:32+00:00", "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc.", "author": {"name": "gurufocus", "url": "https://www.gurufocus.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/591/normal/7.JPG?1576044783"}}, {"title": "Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova", "url": "http://ct.moreover.com/?a=43109192004&p=1pl&v=1&x=H1fXoEzMMOI36_sSKbv0gQ", "license": "public", "citation_ids": [82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85019710, 85730808, 74609849, 90464258, 82555360, 85730808, 74609849, 90464258, 85019710, 82555360, 85730808, 74609849, 90464258, 85019710], "posted_on": "2020-09-17T04:50:08+00:00", "summary": "7:30am EDT SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 / / -- Rigel Pharmaceuticals, Inc.", "author": {"name": "PressReleasePoint", "url": "https://www.pressreleasepoint.com/", "image": "https://s3.amazonaws.com/weyland.altmetric.com/news_sources/logos/000/004/765/normal/point.PNG?1576468755"}}]}, "score": 170.05, "images": {"small": "https://badges.altmetric.com/?size=64&score=171&types=mmmttttt", "medium": "https://badges.altmetric.com/?size=100&score=171&types=mmmttttt", "large": "https://badges.altmetric.com/?size=180&score=171&types=mmmttttt"}}